<?xml version='1.0' encoding='utf-8'?>
<document id="18640471"><sentence text="Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy." /><sentence text="The pharmacologic effects of warfarin might be altered by various factors, including drug-drug interaction" /><sentence text="" /><sentence text="A 49-year-old Japanese man (height, 174 cm; weight, 68 kg) presented with a 20-month history of malignant lymphoma (diffuse large B cell lymphoma, clinical stage IV)" /><sentence text=" He was treated with a combination of rituximab chemotherapy and etoposide, cisplatin, high-dose cytarabine, and methyl-prednisolone (R-ESHAP)"><entity charOffset="65-74" id="DDI-PubMed.18640471.s5.e0" text="etoposide" /><entity charOffset="76-85" id="DDI-PubMed.18640471.s5.e1" text="cisplatin" /><entity charOffset="97-107" id="DDI-PubMed.18640471.s5.e2" text="cytarabine" /><entity charOffset="113-132" id="DDI-PubMed.18640471.s5.e3" text="methyl-prednisolone" /><entity charOffset="134-141" id="DDI-PubMed.18640471.s5.e4" text="R-ESHAP" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e0" e2="DDI-PubMed.18640471.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e0" e2="DDI-PubMed.18640471.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e0" e2="DDI-PubMed.18640471.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e0" e2="DDI-PubMed.18640471.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e0" e2="DDI-PubMed.18640471.s5.e4" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e1" e2="DDI-PubMed.18640471.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e1" e2="DDI-PubMed.18640471.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e1" e2="DDI-PubMed.18640471.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e1" e2="DDI-PubMed.18640471.s5.e4" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e2" e2="DDI-PubMed.18640471.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e2" e2="DDI-PubMed.18640471.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e2" e2="DDI-PubMed.18640471.s5.e4" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e3" e2="DDI-PubMed.18640471.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18640471.s5.e3" e2="DDI-PubMed.18640471.s5.e4" /></sentence><sentence text=" He had been receiving warfarin for the secondary prevention of pulmonary embolism with deep venous thrombosis" /><sentence text=" When R-ESHAP was started, international normalized ratio (INR) increased from 1 to 5" /><sentence text=" This phenomenon was observed again in the second R-ESHAP" /><sentence text=" The INR was increased from 2" /><sentence text="44 to 4" /><sentence text="71 during chemotherapy but was returned to within the normal range (1" /><sentence text="05; normal range: 0" /><sentence text="81-1" /><sentence text="009) 5 days after chemotherapy was completed" /><sentence text="" /><sentence text="In this patient, R-ESHAP chemotherapy might have affected warfarin anticoagulation sensitivity; thus, careful monitoring of INR is essential, particularly in patients receiving warfarin who undergo R-ESHAP chemotherapy" /><sentence text="" /></document>